1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-30031
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Wenjia-
dc.contributor.authorWong, Chong Boon Nigel-
dc.contributor.authorWang, Yi-
dc.contributor.authorZemlyanska, Yaroslava-
dc.contributor.authorButani, Dimple-
dc.contributor.authorVirabhak, Suchin-
dc.contributor.authorMatchar, David Bruce-
dc.contributor.authorPrapinvanich, Thittaya-
dc.contributor.authorTeerawattananon, Yot-
dc.date.accessioned2024-02-29T13:27:27Z-
dc.date.available2024-02-29T13:27:27Z-
dc.date.issued2023-11-24-
dc.identifier.issn2296-2565de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/30031-
dc.description.abstractObjective: This study aimed to quantify heterogeneity in the value for money of precision medicine (PM) by application types across contexts and conditions and to quantify sources of heterogeneity to areas of particular promises or concerns as the field of PM moves forward. Methods: A systemic search was performed in Embase, Medline, EconLit, and CRD databases for studies published between 2011 and 2021 on cost-effectiveness analysis (CEA) of PM interventions. Based on a willingness-to-pay threshold of one-time GDP per capita of each study country, the net monetary benefit (NMB) of PM was pooled using random-effects meta-analyses. Sources of heterogeneity and study biases were examined using random-effects meta-regressions, jackknife sensitivity analysis, and the biases in economic studies checklist. Results: Among the 275 unique CEAs of PM, publicly sponsored studies found neither genetic testing nor gene therapy cost-effective in general, which was contradictory to studies funded by commercial entities and early stage evaluations. Evidence of PM being cost-effective was concentrated in a genetic test for screening, diagnosis, or as companion diagnostics (pooled NMBs, $48,152, $8,869, $5,693, p < 0.001), in the form of multigene panel testing (pooled NMBs = $31,026, p < 0.001), which only applied to a few disease areas such as cancer and high-income countries. Incremental effectiveness was an essential value driver for varied genetic tests but not gene therapy. Conclusion: Precision medicine’s value for money across application types and contexts was difficult to conclude from published studies, which might be subject to systematic bias. The conducting and reporting of CEA of PM should be locally based and standardized for meaningful comparisons.de_CH
dc.language.isoende_CH
dc.publisherFrontiers Research Foundationde_CH
dc.relation.ispartofFrontiers in Public Healthde_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectPrecision medicinede_CH
dc.subjectMedical geneticsde_CH
dc.subjectEconomic evaluationde_CH
dc.subjectValue for moneyde_CH
dc.subjectSystematic reviewde_CH
dc.subjectMeta-analysisde_CH
dc.subjectCost effectivenessde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titleMapping the value for money of precision medicine : a systematic literature review and meta-analysisde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
dc.identifier.doi10.3389/fpubh.2023.1151504de_CH
dc.identifier.doi10.21256/zhaw-30031-
zhaw.funding.euNode_CH
zhaw.issue1151504de_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume11de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedW: Spitzenpublikationde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
File Description SizeFormat 
2023_Chen-etal_Mapping-the-value-for-money-of-precision-medicine.pdf1.78 MBAdobe PDFThumbnail
View/Open
Show simple item record
Chen, W., Wong, C. B. N., Wang, Y., Zemlyanska, Y., Butani, D., Virabhak, S., Matchar, D. B., Prapinvanich, T., & Teerawattananon, Y. (2023). Mapping the value for money of precision medicine : a systematic literature review and meta-analysis. Frontiers in Public Health, 11(1151504). https://doi.org/10.3389/fpubh.2023.1151504
Chen, W. et al. (2023) ‘Mapping the value for money of precision medicine : a systematic literature review and meta-analysis’, Frontiers in Public Health, 11(1151504). Available at: https://doi.org/10.3389/fpubh.2023.1151504.
W. Chen et al., “Mapping the value for money of precision medicine : a systematic literature review and meta-analysis,” Frontiers in Public Health, vol. 11, no. 1151504, Nov. 2023, doi: 10.3389/fpubh.2023.1151504.
CHEN, Wenjia, Chong Boon Nigel WONG, Yi WANG, Yaroslava ZEMLYANSKA, Dimple BUTANI, Suchin VIRABHAK, David Bruce MATCHAR, Thittaya PRAPINVANICH und Yot TEERAWATTANANON, 2023. Mapping the value for money of precision medicine : a systematic literature review and meta-analysis. Frontiers in Public Health. 24 November 2023. Bd. 11, Nr. 1151504. DOI 10.3389/fpubh.2023.1151504
Chen, Wenjia, Chong Boon Nigel Wong, Yi Wang, Yaroslava Zemlyanska, Dimple Butani, Suchin Virabhak, David Bruce Matchar, Thittaya Prapinvanich, and Yot Teerawattananon. 2023. “Mapping the Value for Money of Precision Medicine : A Systematic Literature Review and Meta-Analysis.” Frontiers in Public Health 11 (1151504). https://doi.org/10.3389/fpubh.2023.1151504.
Chen, Wenjia, et al. “Mapping the Value for Money of Precision Medicine : A Systematic Literature Review and Meta-Analysis.” Frontiers in Public Health, vol. 11, no. 1151504, Nov. 2023, https://doi.org/10.3389/fpubh.2023.1151504.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.